Comprehensive magnetic resonance imaging for breast cancer


Cite item

Full Text

Abstract

AIM: To enhance the efficiency of diagnosis of breast tumors by comprehensive magnetic resonance imaging (MRI) involving dynamic contrast-enhanced magnetic resonance mammography (MRM) and magnetic resonance spectroscopy (MRS)/MATERIAL AND METHODS: Eighty-seven women aged 32 to 75 years with breast neoplasms were examined. MRM was performed on a Philips Achieva 3.0T TX scanner. The MRI protocol consisted of axial fat-suppressed T1- and T2-weighted spin-echo images and 8 postcontrast dynamic series. Changes in contrast-enhanced MRI of breast cancer (BC) were estimated by constructing the signal intensity-time curves. MRS was carried out using a PRESS sequence/RESULTS: Dynamic MRM determined type III signal intensity-time curve in 83.9% of the patients with BC and type II curve in 16.1% of those with breast malignancies and in 33.3% of those with breast fibroadenomas. Type I signal intensity-time curve was identified in 66.7% of the cases of fibroadenomas. Elevated choline concentrations in the malignancies were detected in 17.7% of cases. Their tumors were larger than 2 cm. The choline peak in the malignancies could not be revealed in the other cases, which was associated to the large voxel size exceeding the mass size. There was a drastic fall in the signal-to-noise ratio with smaller voxel sizes. Furthermore, higher choline levels were determined in 9.5% of the fibroadenoma cases. Comparison of MRS findings before and after contrast injection revealed the advantage of the latter, which is primarily attributed to the more accurate voxel position on the tumor than that during non-contrast-enhanced MRS/CONCLUSION: Dynamic intravenous contrast-enhanced MRM is an effective method for the differential diagnosis of breast masses. MRS cannot be included in the standard study protocol for women with breast masses for the present.

About the authors

N V Meladze

Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава РФ; Первый МГМУ им. И.М. Сеченова Минздрава РФ

Email: meladze_nina@mail.ru

S K Ternovoĭ

Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава РФ; Первый МГМУ им. И.М. Сеченова Минздрава РФ

M A Shariia

Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава РФ

A E Solopova

Первый МГМУ им. И.М. Сеченова Минздрава РФ

References

  1. Stewart B., Klrihus P. World Health Organisation. World Cancer Report. International Agency on Research for Cancer. Lion: IARC Press 2003: 188-190.
  2. Злокачественные заболевания в России в 2010 году (заболеваемость и смертность). Под. ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М: ФГБУ "МНИОИ им. П.А. Герцена Минздравсоцразвития России" 2012; 260.
  3. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Вестн РОНЦ им. H.H. Блохина РАМН 2006; 3: 132.
  4. Давыдов М.И., Летягин В.П. Практическая маммология 2007: 6-10.
  5. Фомин Ю.А., Саманов B.C. Рентгеноанатомический атлас молочных желез. Под ред. В.Ф. Семиглазова. 2003: 168.
  6. Silverstein M.J., Recht A., Lagios M.J.D. et al. Special report: Consensus conference HI. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg 2009; 209 (4): 504-520.
  7. Корженкова Г.П., Лукьянченко А.Б., Зернов Д.И. Возможности магнитно-резонанснои? томографии в алгоритме обследования пациентов с заболеваниями молочной железы. Маммология 2006; 3: 5-10.
  8. Труфанов Г.Е., Серебряков С.В., Юхно Е.А. МРТ в маммологии. СПб: Элби 2009; 201.
  9. Bolan P.J., Nelson M., Yee T.D., Garwood M. Imaging in breast cancer: Magnetic resonance spectroscopy. Breast Cancer Res 2005; 7: 149-152.
  10. Труфанов Г.Е. Лучевая диагностика заболеваний молочных желез: руководство для врачей. СПб: ЭЛБИ 2006; 232.
  11. Сергеев П.В., Панов В.О., Волобуев A.B. и др. Новые технологии в диагностике опухолевых заболеваний молочной железы с использованием магнитно-резонансных контрастных средств. Мед визуализация 2005; 3: 104-119.
  12. Parker P.B, Bizzi A., Stefano N. et al. Clinical MR spectroscopy. Techniques and Aplications. Cambridge 2010: 229-230.
  13. Baek H.-M., Chen J.-H., Nie K. et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009; 251 (3): 653-662.
  14. Вolan P.J., Meisamy S., Baker E.H. et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003; 50: 1134-1143.
  15. Tozaki M., Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy. Am J Roentgenol 2009; 193 (3): 840-849.
  16. Baek H.-M., Chen J.-H., Yu H. J. et al. Detection of choline signal in human breast lesions with chemical-shift imaging. J Magnet Resonance Imag 2008; 27 (5): 1114-1121.
  17. Sardanelli F., Fausto A., Di Leo G. et al. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. Am J Roentgenol 2009; 192 (6): 1608-1617.
  18. Tse G.M.K., Cheung H.S., Pang L.M. et al. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol 2003; 181 (5): 1267-1272.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies